Log In Sign up
The largest database of trusted experimental protocols

Calbiochem kinase inhibitors

Manufactured by Merck Group
Visit Supplier
Sourced in Germany

Calbiochem kinase inhibitors are a line of laboratory reagents manufactured by Merck Group. These inhibitors are designed to selectively target specific kinases, which are enzymes that play a crucial role in cellular signaling pathways. Kinase inhibitors are widely used in biochemical research to study the function and regulation of various cellular processes.

Automatically generated - may contain errors

Lab products found in correlation

Gefitinib, by GlaxoSmithKline (2 mentions) Sapitinib, by GlaxoSmithKline (2 mentions) Afatinib, by GlaxoSmithKline (2 mentions) Poziotinib, by GlaxoSmithKline (2 mentions) Anticancer library, by Selleck Chemicals (2 mentions) Akr1b10, by Selleck Chemicals (2 mentions) Tykerb, by GlaxoSmithKline (2 mentions) Erlotinib osi 774, by Selleck Chemicals (1 mentions)

Spelling variants of this product

Calbiochem (19 citations)

2 protocols using calbiochem kinase inhibitors

1

High-Throughput Kinase Inhibitor Screening

Check if the same lab product or an alternative is used in the 5 most similar protocols
In collaboration with Cancer Research Technology Ldt UK (CRT), 1097 compounds were selected for the compound screen (see supplementary material, Table S2). GlaxoSmithKline (GSK) provided 886 small molecule kinase inhibitors comprising 365 ('PKIS') and 521 ('PKIS2') compounds on which there are published data (see supplementary material, Table S2) 36, 37. Also screened were 160 Calbiochem kinase inhibitors (Merck KGaA, Darmstadt, Germany) provided by CRT, an Anticancer Library (n = 43) (Selleckchem, Houston, TX, USA), and eight compounds reported to be inhibitors of aldo‐keto reductase family 1 member B10 (AKR1B10; Selleckchem) 38. Six commercially available epidermal growth factor receptor/erythroblastic leukaemia viral oncogene homologue (EGFR/ERBB) family inhibitors, either FDA‐approved or currently in clinical trials 39, 40, 41, 42, were purchased [Selleckchem: erlotinib (OSI‐774), gefitinib (ZD1839), sapitinib (AZD8931), afatinib (BIBW 2992), poziotinib (NOV120101; HM781‐36B)] and lapatinib (Tykerb®; GSK).
Scheipl S., Barnard M., Cottone L., Jorgensen M., Drewry D.H., Zuercher W.J., Turlais F., Ye H., Leite A.P., Smith J.A., Leithner A., Möller P., Brüderlein S., Guppy N., Amary F., Tirabosco R., Strauss S.J., Pillay N, & Flanagan A.M. (2016). EGFR inhibitors identified as a potential treatment for chordoma in a focused compound screen. The Journal of Pathology, 239(3), 320-334.
+ Open protocol
+ Expand
2

Kinase Inhibitor Compound Screen

Check if the same lab product or an alternative is used in the 5 most similar protocols
In collaboration with Cancer Research Technology Ldt UK (CRT), 1097 compounds were selected for the compound screen (see supplementary material, Table S2). GlaxoSmithKline (GSK) provided 886 small molecule kinase inhibitors comprising 365 (’PKIS’) and 521 (’PKIS2’) compounds on which there are published data (see supplementary material, Table S2) [36 (link),37 (link)]. Also screened were 160 Calbiochem kinase inhibitors (Merck KGaA, Darmstadt, Germany) provided by CRT, an Anticancer Library (n = 43) (Selleckchem, Houston, TX, USA), and eight compounds reported to be inhibitors of aldo-keto reductase family 1 member B10 (AKR1B10; Selleckchem) [38 (link)]. Six commercially available epidermal growth factor receptor/erythroblastic leukaemia viral oncogene homologue (EGFR/ERBB) family inhibitors, either FDA-approved or currently in clinical trials [39 (link)–42 (link)], were purchased [Selleckchem: erlotinib (OSI-774), gefitinib (ZD1839), sapitinib (AZD8931), afatinib (BIBW 2992), poziotinib (NOV120101; HM781-36B)] and lapatinib (Tykerb®; GSK).
Scheipl S., Barnard M., Cottone L., Jorgensen M., Drewry D.H., Zuercher W.J., Turlais F., Ye H., Leite A.P., Smith J.A., Leithner A., Möller P., Brüderlein S., Guppy N., Amary F., Tirabosco R., Strauss S.J., Pillay N, & Flanagan A.M. (2016). EGFR inhibitors identified as a potential treatment for chordoma in a focused compound screen. The Journal of Pathology, 239(3), 320-334.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!